Free Trial
NASDAQ:ERNA

Ernexa Therapeutics (ERNA) Stock Price, News & Analysis

Ernexa Therapeutics logo
$1.36 +0.17 (+13.81%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 0.00 (0.00%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ernexa Therapeutics Stock (NASDAQ:ERNA)

Advanced

Key Stats

Today's Range
$1.25
$1.36
50-Day Range
$1.10
$1.91
52-Week Range
$1.09
$18.75
Volume
165,470 shs
Average Volume
278,991 shs
Market Capitalization
$10.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Ernexa Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

ERNA MarketRank™: 

Ernexa Therapeutics scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ernexa Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ernexa Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ernexa Therapeutics has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Ernexa Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.11% of the float of Ernexa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ernexa Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ernexa Therapeutics has recently decreased by 17.22%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ernexa Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Ernexa Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.11% of the float of Ernexa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ernexa Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ernexa Therapeutics has recently decreased by 17.22%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Ernexa Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for ERNA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Ernexa Therapeutics is held by insiders.

  • Percentage Held by Institutions

    70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ernexa Therapeutics' insider trading history.
Receive ERNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ernexa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ERNA Stock News Headlines

Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
See More Headlines

ERNA Stock Analysis - Frequently Asked Questions

Ernexa Therapeutics' stock was trading at $4.41 at the beginning of 2025. Since then, ERNA stock has decreased by 70.4% and is now trading at $1.3050.

Ernexa Therapeutics Inc. (NASDAQ:ERNA) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.61) earnings per share for the quarter.

Ernexa Therapeutics's stock reverse split on Thursday, June 12th 2025.The 1-15 reverse split was announced on Tuesday, June 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ernexa Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV).

Company Calendar

Last Earnings
8/13/2025
Today
10/06/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ERNA
CIK
748592
Employees
10
Year Founded
1953

Profitability

EPS (Trailing Twelve Months)
($8.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.54 million
Net Margins
N/A
Pretax Margin
-8,948.77%
Return on Equity
N/A
Return on Assets
-682.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.81
Quick Ratio
1.81

Sales & Book Value

Annual Sales
$488 thousand
Price / Sales
18.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
2.39

Miscellaneous

Outstanding Shares
7,671,000
Free Float
7,327,000
Market Cap
$9.17 million
Optionable
No Data
Beta
5.62

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ERNA) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners